6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis.

      American journal of respiratory and critical care medicine

      Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, therapeutic use, Blood Proteins, analysis, Bronchitis, drug therapy, pathology, Chronic Disease, Cross-Over Studies, Dyspnea, Eosinophil Granule Proteins, Eosinophilia, Female, Fibrinogen, Follow-Up Studies, Forced Expiratory Volume, drug effects, Forecasting, Glucocorticoids, Humans, Inflammation Mediators, Male, Middle Aged, Placebos, Prednisone, Quality of Life, Reproducibility of Results, Ribonucleases, Single-Blind Method, Smoking, adverse effects, Sputum, cytology

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A reliable predictor of benefit from corticosteroid treatment in patients with chronic airflow limitation is needed. In a single-blind, sequential crossover trial of placebo and prednisone (30 mg/day) treatment, with each given for 2 wk, we investigated whether an increased proportion of sputum eosinophils (>= 3%) predicts a beneficial effect of prednisone in smokers with severe obstructive bronchitis. Patients were seen before and after each treatment. Clinical measurements were made blind to the laboratory findings and vice-versa. Eighteen of 20 patients completed the study. Eight had sputum eosinophilia and similar clinical and physiologic characteristics to those of 10 patients without a finding of sputum eosinophilia. Only in patients with sputum eosinophilia did prednisone, as compared with placebo, produce a statistically significant and clinically important mean effect on effort dyspnea of 0.8 (95% confidence interval [CI]: 0.3 to 1.2), p = 0.008, and in quality of life of 1.96 (95% CI: 0.5 to 3.3), p = 0.01, associated with a small improvement in FEV1 of 0.11 L (95% CI: - 0.04 to 0.23 L), p = 0.05. In these patients, prednisone also produced a significant decline in the median sputum eosinophil percentage, from 9.7% to 0.5% (p = 0.002), eosinophil cationic protein (ECP), from 6, 000 microgram/L to 1,140 microgram/L (p < 0.001), and fibrinogen, from 25. 3 mg/L to 5.4 mg/L (p < 0.001). These findings indicate that in smokers with severe airflow limitation, sputum eosinophilia predicts a beneficial effect of prednisone treatment. Improvement in FEV1, after prednisone treatment in this population, is small, and may not be appreciated in clinical practice.

          Related collections

          Author and article information

          Journal
          9817701
          10.1164/ajrccm.158.5.9804028

          Comments

          Comment on this article